163 related articles for article (PubMed ID: 10490816)
1. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
Bongarzone I; Vigano E; Alberti L; Mondellini P; Uggeri M; Pasini B; Borrello MG; Pierotti MA
Oncogene; 1999 Aug; 18(34):4833-8. PubMed ID: 10490816
[TBL] [Abstract][Full Text] [Related]
2. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
Hennige AM; Lammers R; Arlt D; Höppner W; Strack V; Niederfellner G; Seif FJ; Häring HU; Kellerer M
Mol Cell Endocrinol; 2000 Sep; 167(1-2):69-76. PubMed ID: 11000521
[TBL] [Abstract][Full Text] [Related]
3. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
4. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
Pelet A; Geneste O; Edery P; Pasini A; Chappuis S; Atti T; Munnich A; Lenoir G; Lyonnet S; Billaud M
J Clin Invest; 1998 Mar; 101(6):1415-23. PubMed ID: 9502784
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
6. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
Asai N; Murakami H; Iwashita T; Takahashi M
J Biol Chem; 1996 Jul; 271(30):17644-9. PubMed ID: 8663426
[TBL] [Abstract][Full Text] [Related]
7. Grb2 binding to the different isoforms of Ret tyrosine kinase.
Alberti L; Borrello MG; Ghizzoni S; Torriti F; Rizzetti MG; Pierotti MA
Oncogene; 1998 Sep; 17(9):1079-87. PubMed ID: 9764818
[TBL] [Abstract][Full Text] [Related]
8. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
9. A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.
Arlt DH; Baur B; Wagner B; Höppner W
Oncogene; 2000 Jul; 19(30):3445-8. PubMed ID: 10918602
[TBL] [Abstract][Full Text] [Related]
10. Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.
Melillo RM; Santoro M; Ong SH; Billaud M; Fusco A; Hadari YR; Schlessinger J; Lax I
Mol Cell Biol; 2001 Jul; 21(13):4177-87. PubMed ID: 11390647
[TBL] [Abstract][Full Text] [Related]
11. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.
Chappuis-Flament S; Pasini A; De Vita G; Ségouffin-Cariou C; Fusco A; Attié T; Lenoir GM; Santoro M; Billaud M
Oncogene; 1998 Dec; 17(22):2851-61. PubMed ID: 9879991
[TBL] [Abstract][Full Text] [Related]
12. Key role of Shc signaling in the transforming pathway triggered by Ret/ptc2 oncoprotein.
Mercalli E; Ghizzoni S; Arighi E; Alberti L; Sangregorio R; Radice MT; Gishizky ML; Pierotti MA; Borrello MG
Oncogene; 2001 Jun; 20(27):3475-85. PubMed ID: 11429694
[TBL] [Abstract][Full Text] [Related]
13. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
16. The role of amino acids surrounding tyrosine 1062 in ret in specific binding of the shc phosphotyrosine-binding domain.
Ishiguro Y; Iwashita T; Murakami H; Asai N; Iida K; Goto H; Hayakawa T; Takahashi M
Endocrinology; 1999 Sep; 140(9):3992-8. PubMed ID: 10465268
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.
Kato M; Iwashita T; Takeda K; Akhand AA; Liu W; Yoshihara M; Asai N; Suzuki H; Takahashi M; Nakashima I
Mol Biol Cell; 2000 Jan; 11(1):93-101. PubMed ID: 10637293
[TBL] [Abstract][Full Text] [Related]
18. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
19. The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.
Carlomagno F; Salvatore G; Cirafici AM; De Vita G; Melillo RM; de Franciscis V; Billaud M; Fusco A; Santoro M
Cancer Res; 1997 Feb; 57(3):391-5. PubMed ID: 9012462
[TBL] [Abstract][Full Text] [Related]
20. Evidence of both extra- and intracellular cysteine targets of protein modification for activation of RET kinase.
Akhand AA; Ikeyama T; Akazawa S; Kato M; Hossain K; Takeda K; Suzuki H; Takahashi M; Nakashima I
Biochem Biophys Res Commun; 2002 Apr; 292(4):826-31. PubMed ID: 11944888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
